Infliximab
- Generic Name
- Infliximab
- Brand Names
- Avsola, Flixabi, Inflectra, Remicade, Renflexis, Zessly, Remsima
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 170277-31-3
- Unique Ingredient Identifier
- B72HH48FLU
- Background
Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions . Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammato...
- Indication
用于治疗：
⑴类风湿性关节炎：本品常与甲氨蝶呤合用于中重度活动性类风湿性关节炎；
⑵克罗恩病及瘘管性克罗恩病；
⑶强直性脊柱炎等自身免疫性疾病，以减轻症状和体征，改善身体机能，预防患者残疾。
⑷用于银屑病关节炎的治疗【美国FDA已批准；英国风湿病学会/英国风湿病卫生专业人员协会《BSR／BHPR—应用生物制剂治疗银屑病关节炎指南》2012版；欧洲抗风湿病联盟《EULAR—银屑病关节炎药 物治疗管理建议》2011版
】。
⑸用于6岁及以上儿童溃疡性结肠炎的治疗【美国FDA已批准；中华医学会内科学会《炎症性肠病诊断与治疗的共识意见》；中华医学会消化病学分会炎症性肠病学组《英夫利西治疗克罗恩病的推荐方案（2011年】。
- Associated Conditions
- Ankylosing Spondylitis (AS), Chronic Plaque Psoriasis, Fistulizing Crohn's Disease, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Rheumatoid Arthritis, Moderately to Severely Active Ulcerative Colitis, Pediatric Crohn’s Disease, Psoriatic Arthritis
- Associated Therapies
- -
EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2018-09-20
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Rennes University Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT03679546
- Locations
- 🇫🇷
Centre Hospitalier Universitaire d'Amiens-Picardie, Amiens, France
🇫🇷Centre Hospitalier Universitaire de Besançon, Besançon, France
🇫🇷Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 2274
- Registration Number
- NCT03662919
- Locations
- 🇫🇷
Research Site, Toulon, Provence-Alpes-Côte d'Azur, France
🇫🇷Research Site 2, La Rochelle, Nouvelle-Aquitaine, France
🇫🇷Research Site 3, Paris, Ile De France, France
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 84
- Registration Number
- NCT03596645
- Locations
- 🇺🇸
Children's Hospital Colorado and University of Colorado, Aurora, Colorado, United States
🇪🇸Hosp Regional Univ de Malaga, Málaga, Spain
🇺🇸University of California San Francisco, San Francisco, California, United States
Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients
- Conditions
- Interventions
- First Posted Date
- 2018-03-02
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Hikma Pharmaceuticals LLC
- Target Recruit Count
- 157
- Registration Number
- NCT03452501
- Locations
- 🇸🇦
King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
🇸🇦King Saud Medical City, Riyadh, Saudi Arabia
🇸🇦King Abdulaziz University Hospital, Jeddah, Saudi Arabia
Abdominal Ultrasound With Doppler and Peripheral Hemogram in Assesment Inflammatory Bowel Disease
- First Posted Date
- 2018-02-26
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 60
- Registration Number
- NCT03445624
- Locations
- 🇪🇬
Hyam Fathy, Assiut, Egypt
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
- Conditions
- Interventions
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 400
- Registration Number
- NCT03414502
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease
- Conditions
- Interventions
- First Posted Date
- 2017-12-13
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 53
- Registration Number
- NCT03371095
- Locations
- 🇫🇷
CHRU Amiens, Amiens, France
🇫🇷CHU Bordeaux, Bordeaux, France
🇫🇷Hôpital Saint André, Bordeaux, France
Evaluation of the Clinical and Immunological Impact of Two Therapeutic Strategies in Chronic Inflammatory Diseases
- Conditions
- Interventions
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- University Hospital, Lille
- Target Recruit Count
- 9
- Registration Number
- NCT03370601
- Locations
- 🇫🇷
CHRU, Hôpital Claude Huriez, Lille, France
Molecular Signatures in Inflammatory Skin Disease
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Prof. Dr. Stephan Weidinger
- Target Recruit Count
- 300
- Registration Number
- NCT03358693
- Locations
- 🇩🇪
Department of Dermatology, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany
Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- IRCCS Burlo Garofolo
- Target Recruit Count
- 9
- Registration Number
- NCT03221166
- Locations
- 🇮🇹
Gastroenterologia e Nutrizione Pediatrica, Azienda Ospedaliero Universitaria Meyer, Firenze, Toscana, Italy
🇮🇹IRCCS Burlo Garofolo, Trieste, Friuli Venezia Giulia, Italy
🇮🇹Fondazione MBBM , Azienda Ospedaliera San Gerardo - Università Milano Bicocca, Monza, Lombardia, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.